




**Figure S2** Nodesplit analysis of PFS (a), OS (b), ORR (c) for overall population. Nodesplit analysis of OS (d) for liver metastatic population. Nodesplit analysis of grade 3 to 5 tr-AEs (e). \*PFS, progression free survival; OS, overall survival; ORR, objective response rate; tr-AEs, treatment-related adverse events.




**Figure S3** Publication bias on PFS estimated by funnel plot. Overall population (a). Patients with PD-L1 < 1% (b). Patients with  $1 \leq \text{PD-L1} < 50\%$  (c). Patients with PD-L1  $\geq 50\%$  (d). Patients with liver metastases (e). \*PFS, progression free survival; PD-L1, program death ligand 1.




**Figure S4** Publication bias on PFS estimated by Egger's funnel plot. Overall population (a). Patients with PD-L1 < 1% (b). Patients with 1% ≤ PD-L1 < 50% (c). Patients with PD-L1 ≥ 50% (d). Patients with liver metastases (e). \*PFS, progression free survival; PD-L1, program death ligand 1.




**Figure S5** Publication bias on PFS estimated by Begg's funnel plot. Overall population (a). Patients with PD-L1 < 1% (b). Patients with 1 ≤ PD-L1 < 50% (c). Patients with PD-L1 ≥ 50% (d). Patients with liver metastases (e). \*PFS, progression free survival; PD-L1, program death ligand 1.




**Figure S6** Publication bias on OS estimated by funnel plot. Overall population (a). Patients with PD-L1 < 1% (b). Patients with 1 ≤ PD-L1 < 50% (c). Patients with PD-L1 ≥ 50% (d). Patients with liver metastases (e). \*OS, overall survival; PD-L1, program death ligand 1.



**Figure S7** Publication bias on OS estimated by Egger's funnel plot. Overall population (a). Patients with PD-L1 < 1% (b). Patients with 1 ≤ PD-L1 < 50% (c). Patients with PD-L1 ≥ 50% (d). Patients with liver metastases (e). \*OS, overall survival; PD-L1, program death ligand 1.




**Figure S8** Publication bias on OS estimated by Begg's funnel plot. Overall population (a). Patients with PD-L1 < 1% (b). Patients with  $1 \leq \text{PD-L1} < 50\%$  (c). Patients with PD-L1  $\geq 50\%$  (d). Patients with liver metastases (e). \*OS, overall survival; PD-L1, program death ligand 1.




**Figure S9** Publication bias on ORR estimated by funnel plot. Overall population (a). Grade 3 to 5 tr-AEs (b). \*ORR, objective response rate; tr-AEs, treatment-related adverse events.





**Figure S10** Publication bias on ORR estimated by Egger's funnel plot. Overall population (a). Grade 3 to 5 tr-AEs (b). \*ORR, objective response rate; tr-AEs, treatment-related adverse events.



**Figure S11** Publication bias on ORR estimated by Begg's funnel plot. Overall population (a). Grade 3 to 5 tr-AEs (b). \*ORR, objective response rate; tr-AEs, treatment-related adverse events.